Genotypic Resistance of Pyrazinamide but Not Minimum Inhibitory Concentration Is Associated With Longer Time to Sputum Culture Conversion in Patients With Multidrug-resistant Tuberculosis
Pyrazinamide (PZA) resistance in multidrug-resistant tuberculosis (MDR-TB) is common; yet, it is not clear how it affects interim and treatment outcomes. Although rarely performed, phenotypic drug susceptibility testing (pDST) is used to define PZA resistance, but genotypic DST (gDST) and minimum in...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases Jg. 73; H. 9; S. e3511 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
02.11.2021
|
| ISSN: | 1537-6591, 1537-6591 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Pyrazinamide (PZA) resistance in multidrug-resistant tuberculosis (MDR-TB) is common; yet, it is not clear how it affects interim and treatment outcomes. Although rarely performed, phenotypic drug susceptibility testing (pDST) is used to define PZA resistance, but genotypic DST (gDST) and minimum inhibitory concentration (MIC) could be beneficial. We aimed to assess the impact of PZA gDST and MIC on time to sputum culture conversion (SCC) and treatment outcome in patients with MDR-TB.BACKGROUNDPyrazinamide (PZA) resistance in multidrug-resistant tuberculosis (MDR-TB) is common; yet, it is not clear how it affects interim and treatment outcomes. Although rarely performed, phenotypic drug susceptibility testing (pDST) is used to define PZA resistance, but genotypic DST (gDST) and minimum inhibitory concentration (MIC) could be beneficial. We aimed to assess the impact of PZA gDST and MIC on time to sputum culture conversion (SCC) and treatment outcome in patients with MDR-TB.Clinical, microbiological, and treatment data were collected in this cohort study for all patients diagnosed with MDR-TB in Sweden from 1992-2014. MIC, pDST, and whole-genome sequencing of the pncA, rpsA, and panD genes were used to define PZA resistance. A Cox regression model was used for statistical analyses.METHODSClinical, microbiological, and treatment data were collected in this cohort study for all patients diagnosed with MDR-TB in Sweden from 1992-2014. MIC, pDST, and whole-genome sequencing of the pncA, rpsA, and panD genes were used to define PZA resistance. A Cox regression model was used for statistical analyses.Of 157 patients with MDR-TB, 56.1% (n = 88) had PZA-resistant strains and 49.7% (n = 78) were treated with PZA. In crude and adjusted analysis (hazard ratio [HR], 0.49; 95% conficence interval [CI], .29-.82; P = .007), PZA gDST resistance was associated with a 29-day longer time to SCC. A 2-fold decrease in dilutions of PZA MIC for PZA-susceptible strains showed no association with SCC in crude or adjusted analyses (HR, 0.98; 95% CI, .73-1.31; P = .89). MIC and gDST for PZA were not associated with treatment outcome.RESULTSOf 157 patients with MDR-TB, 56.1% (n = 88) had PZA-resistant strains and 49.7% (n = 78) were treated with PZA. In crude and adjusted analysis (hazard ratio [HR], 0.49; 95% conficence interval [CI], .29-.82; P = .007), PZA gDST resistance was associated with a 29-day longer time to SCC. A 2-fold decrease in dilutions of PZA MIC for PZA-susceptible strains showed no association with SCC in crude or adjusted analyses (HR, 0.98; 95% CI, .73-1.31; P = .89). MIC and gDST for PZA were not associated with treatment outcome.In patients with MDR-TB, gDST PZA resistance was associated with a longer time to SCC. Rapid PZA gDST is important to identify patients who may benefit from PZA treatment.CONCLUSIONSIn patients with MDR-TB, gDST PZA resistance was associated with a longer time to SCC. Rapid PZA gDST is important to identify patients who may benefit from PZA treatment. |
|---|---|
| AbstractList | Pyrazinamide (PZA) resistance in multidrug-resistant tuberculosis (MDR-TB) is common; yet, it is not clear how it affects interim and treatment outcomes. Although rarely performed, phenotypic drug susceptibility testing (pDST) is used to define PZA resistance, but genotypic DST (gDST) and minimum inhibitory concentration (MIC) could be beneficial. We aimed to assess the impact of PZA gDST and MIC on time to sputum culture conversion (SCC) and treatment outcome in patients with MDR-TB.BACKGROUNDPyrazinamide (PZA) resistance in multidrug-resistant tuberculosis (MDR-TB) is common; yet, it is not clear how it affects interim and treatment outcomes. Although rarely performed, phenotypic drug susceptibility testing (pDST) is used to define PZA resistance, but genotypic DST (gDST) and minimum inhibitory concentration (MIC) could be beneficial. We aimed to assess the impact of PZA gDST and MIC on time to sputum culture conversion (SCC) and treatment outcome in patients with MDR-TB.Clinical, microbiological, and treatment data were collected in this cohort study for all patients diagnosed with MDR-TB in Sweden from 1992-2014. MIC, pDST, and whole-genome sequencing of the pncA, rpsA, and panD genes were used to define PZA resistance. A Cox regression model was used for statistical analyses.METHODSClinical, microbiological, and treatment data were collected in this cohort study for all patients diagnosed with MDR-TB in Sweden from 1992-2014. MIC, pDST, and whole-genome sequencing of the pncA, rpsA, and panD genes were used to define PZA resistance. A Cox regression model was used for statistical analyses.Of 157 patients with MDR-TB, 56.1% (n = 88) had PZA-resistant strains and 49.7% (n = 78) were treated with PZA. In crude and adjusted analysis (hazard ratio [HR], 0.49; 95% conficence interval [CI], .29-.82; P = .007), PZA gDST resistance was associated with a 29-day longer time to SCC. A 2-fold decrease in dilutions of PZA MIC for PZA-susceptible strains showed no association with SCC in crude or adjusted analyses (HR, 0.98; 95% CI, .73-1.31; P = .89). MIC and gDST for PZA were not associated with treatment outcome.RESULTSOf 157 patients with MDR-TB, 56.1% (n = 88) had PZA-resistant strains and 49.7% (n = 78) were treated with PZA. In crude and adjusted analysis (hazard ratio [HR], 0.49; 95% conficence interval [CI], .29-.82; P = .007), PZA gDST resistance was associated with a 29-day longer time to SCC. A 2-fold decrease in dilutions of PZA MIC for PZA-susceptible strains showed no association with SCC in crude or adjusted analyses (HR, 0.98; 95% CI, .73-1.31; P = .89). MIC and gDST for PZA were not associated with treatment outcome.In patients with MDR-TB, gDST PZA resistance was associated with a longer time to SCC. Rapid PZA gDST is important to identify patients who may benefit from PZA treatment.CONCLUSIONSIn patients with MDR-TB, gDST PZA resistance was associated with a longer time to SCC. Rapid PZA gDST is important to identify patients who may benefit from PZA treatment. |
| Author | Mansjö, Mikael Werngren, Jim Jonsson Nordvall, Michaela Groenheit, Ramona Kuhlin, Johanna Schön, Thomas Davies Forsman, Lina Bruchfeld, Judith Wijkander, Maria Wagrell, Charlotta Jonsson, Jerker |
| Author_xml | – sequence: 1 givenname: Johanna surname: Kuhlin fullname: Kuhlin, Johanna – sequence: 2 givenname: Lina surname: Davies Forsman fullname: Davies Forsman, Lina – sequence: 3 givenname: Mikael surname: Mansjö fullname: Mansjö, Mikael – sequence: 4 givenname: Michaela surname: Jonsson Nordvall fullname: Jonsson Nordvall, Michaela – sequence: 5 givenname: Maria surname: Wijkander fullname: Wijkander, Maria – sequence: 6 givenname: Charlotta surname: Wagrell fullname: Wagrell, Charlotta – sequence: 7 givenname: Jerker surname: Jonsson fullname: Jonsson, Jerker – sequence: 8 givenname: Ramona surname: Groenheit fullname: Groenheit, Ramona – sequence: 9 givenname: Jim surname: Werngren fullname: Werngren, Jim – sequence: 10 givenname: Thomas surname: Schön fullname: Schön, Thomas – sequence: 11 givenname: Judith surname: Bruchfeld fullname: Bruchfeld, Judith |
| BookMark | eNpNjk1LAzEQhoNUUKs3f8Acvawmm027OUrRWqgfaMWjJJvZNrKb1HwI9a_551zRg4dhhpd5Ht4jMnLeISGnjJ4zKvlFY80wSjFB5R45ZIJPi4mQbPTvPiBHMb5RylhNxSH5mqPzabe1DTxitDEp1yD4Fh52QX1ap3prEHROcOcT3Fpn-9zDwm2stsmHHcz8ALgUVLLewSLCZYx-KJHQwItNG1h6t8YAK9sjJA9P25wGwyx3KQf8wT8wxB_WOngYLIMs_pK3w481Ia-L8FctwSprDE3u_BAck_1WdRFP_vaYPF9frWY3xfJ-vphdLouG8zoVDLU0WrWccy10I5G2Uk2w4tIYWk4nJW0FLelUS9kKISuNbYvCGFViKQWyckzOfr3b4N8zxvTa29hg1ymHPsfXsqrqCa8rWZffgxV_AQ |
| CitedBy_id | crossref_primary_10_1080_1120009X_2023_2214473 crossref_primary_10_2147_IDR_S374687 crossref_primary_10_1080_22221751_2024_2447607 crossref_primary_10_1016_S1473_3099_22_00875_1 crossref_primary_10_3390_pharmaceutics16010144 crossref_primary_10_1016_j_jmii_2023_08_013 crossref_primary_10_1002_slct_202300780 crossref_primary_10_1093_gpbjnl_qzae046 crossref_primary_10_1038_s41467_023_43937_1 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. |
| Copyright_xml | – notice: The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. |
| DBID | 7X8 |
| DOI | 10.1093/cid/ciaa1509 |
| DatabaseName | MEDLINE - Academic |
| DatabaseTitle | MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1537-6591 |
| GroupedDBID | --- ..I .2P .I3 .ZR 08P 0R~ 29B 2WC 36B 4.4 48X 53G 5GY 5RE 5VS 5WD 6J9 70D 7X8 AABZA AACGO AACZT AAJKP AAMVS AANCE AAOGV AAPNW AAPQZ AAPXW AAQQT AARHZ AAUAY AAVAP ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABLJU ABNHQ ABNKS ABOCM ABPLY ABPQP ABPTD ABQLI ABQNK ABTLG ABVGC ABWST ABXVV ABZBJ ACGFO ACGFS ACPRK ACUFI ACUTJ ACUTO ACYHN ADBBV ADEYI ADGZP ADHKW ADHZD ADIPN ADNBA ADOCK ADQBN ADRTK ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFIYH AFOFC AFRAH AFXAL AFYAG AGINJ AGKEF AGQXC AGSYK AGUTN AHGBF AHMBA AHMMS AHXPO AIAGR AIJHB AJBYB AJEEA AJNCP ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN AQKUS ATGXG AXUDD BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM C45 CDBKE CS3 CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBS EE~ EMOBN ENERS F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC H13 H5~ HAR HW0 HZ~ IOX J21 JLS JSG JXSIZ KAQDR KBUDW KOP KSI KSN L7B MHKGH MJL ML0 N9A NGC NOMLY NOYVH NU- O9- OAUYM OAWHX OCZFY ODMLO ODZKP OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P P6G PAFKI PEELM PQQKQ Q1. Q5Y RD5 ROX ROZ RUSNO RW1 RXO SJN TCURE TEORI TJX TMA TR2 W8F X7H YAYTL YKOAZ YXANX ~91 ~S- |
| ID | FETCH-LOGICAL-c338t-1eb9dbaf333b5bc9e0f9a6e439dd027620f50207b99f5594beffe5dda2e295e12 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 8 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000720749600187&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1537-6591 |
| IngestDate | Sun Sep 28 02:33:43 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c338t-1eb9dbaf333b5bc9e0f9a6e439dd027620f50207b99f5594beffe5dda2e295e12 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PQID | 2448638498 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2448638498 |
| PublicationCentury | 2000 |
| PublicationDate | 20211102 |
| PublicationDateYYYYMMDD | 2021-11-02 |
| PublicationDate_xml | – month: 11 year: 2021 text: 20211102 day: 02 |
| PublicationDecade | 2020 |
| PublicationTitle | Clinical infectious diseases |
| PublicationYear | 2021 |
| SSID | ssj0011805 |
| Score | 2.4206917 |
| Snippet | Pyrazinamide (PZA) resistance in multidrug-resistant tuberculosis (MDR-TB) is common; yet, it is not clear how it affects interim and treatment outcomes.... |
| SourceID | proquest |
| SourceType | Aggregation Database |
| StartPage | e3511 |
| Title | Genotypic Resistance of Pyrazinamide but Not Minimum Inhibitory Concentration Is Associated With Longer Time to Sputum Culture Conversion in Patients With Multidrug-resistant Tuberculosis |
| URI | https://www.proquest.com/docview/2448638498 |
| Volume | 73 |
| WOSCitedRecordID | wos000720749600187&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Jb9QwFLaAIsSFHVE2PSSuVidOnMQnhCoKlehoBEXMrfKW1hJjTxOnUn8bf47nxKMeuCBxjWLLyVv8vZ2Q9_jfJe-YooVihlZM11RoUVPTGZXGFXLB9TRsolku2_VarLLDbchplTudOClqE3TykR_gNdQir1Si_bC9pGlqVIqu5hEat8leiVAmcXWzvokiFO2UwohC3dCaiyInvqMRf6CR1PjxEvGQ-EsNT3fL0cP_PdUj8iCjSvg4s8Fjcsv6J-TeSY6bPyW_P1sf4vXWafhmhwQZkdYQOlhd96m_tNw4Y0GNEZYhwonzbjNu4NhfOOVSFB4OU3Wjzy124XiAHVmtgZ8uXsDXkNyDkCpKIAb4vh0j7jA37LRp-dXsmAPnYTX3ch3mlVMJsOnHc9rno0U4HZXt9fgr4INn5MfRp9PDLzSPbaAa7d1IC6uEUbIry1JxpYVddELWFpGPMWgE12zRcQSpjRKiQ3umUilzhRsjmWWC24I9J3d88PYFgc60rCpLk0BIJYWRC6PKcqF46jpmdLNP3u3IcoZikWId0tswDmc3hHn5D--8IvdZylVJ7mL2mux1KPr2Dbmrr6Ib-rcTV_0B1R_d4w |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Genotypic+Resistance+of+Pyrazinamide+but+Not+Minimum+Inhibitory+Concentration+Is+Associated+With+Longer+Time+to+Sputum+Culture+Conversion+in+Patients+With+Multidrug-resistant+Tuberculosis&rft.jtitle=Clinical+infectious+diseases&rft.au=Kuhlin%2C+Johanna&rft.au=Davies+Forsman%2C+Lina&rft.au=Mansj%C3%B6%2C+Mikael&rft.au=Jonsson+Nordvall%2C+Michaela&rft.date=2021-11-02&rft.issn=1537-6591&rft.eissn=1537-6591&rft.volume=73&rft.issue=9&rft.spage=e3511&rft_id=info:doi/10.1093%2Fcid%2Fciaa1509&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1537-6591&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1537-6591&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1537-6591&client=summon |